Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements of brain-reactive B cells in the blood

Clinical Immunology

Volumn 152, Issue 1-2, 2014, Pages 20-24

  Kuerten, Stefanie ^a   Pommerschein, Giovanna ^b   Barth, Stefanie K ^b   Hohmann, Christopher ^b   Milles, Bianca ^b   Sammer, Fabian W ^b   Duffy, Cathrina E ^b   Wunsch, Marie ^a   Rovituso, Damiano M ^a   Schroeter, Michael ^b   Addicks, Klaus ^b   Kaiser, Claudia C ^b   Lehmann, Paul V ^c,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Cellular Technology Limited   (United States)

Author keywords

Autoimmunity; ; B cells; ; Blood; ; ELISPOT; ; Multiple sclerosis

Indexed keywords

BRAIN ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRAIN REACTIVE B LYMPHOCYTE; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONINFLAMMATORY NEUROLOGICAL DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCLONAL STIMULATION; PRIORITY JOURNAL; RISK ASSESSMENT; YOUNG ADULT;

AUTOIMMUNITY;; B CELLS;; BLOOD;; ELISPOT;; MULTIPLE SCLEROSIS;

ADULT; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS;

EID: 84896979985     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.02.014     Document Type: Article

References (20)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
3. Mayer M.C., Hohlfeld R., Meinl E. Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. J. Neurol. Sci. 2012, 319:2-7.
4. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
5. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
6. Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 2012, 13:507-514.
7. Weber M.S., Hemmer B., Cepok S. The role of antibodies in multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:239-245.
8. Srivastava R., Aslam M., Kalluri S.R., Schirmer L., Buck D., Tackenberg B., Rothhammer V., Chan A., Gold R., Berthele A., Bennett J.L., Korn T., Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 2012, 367:115-123.
9. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 2007, 356:371-378.
10. Pelayo R., Tintoré M., Montalban X., Rovira A., Espejo C., Reindl M., Berger T. Antimyelin antibodies with no progression to multiple sclerosis. N. Engl. J. Med. 2007, 356:426-428.
11. Pinna D., Corti D., Jarrossay D., Sallusto F., Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 2009, 39:1260-1270.
12. Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 2012, 8:613-623.
13. Bankoti J., Apeltsin L., Hauser S.L., Allen S., Albertolle M.E., Witkowska H.E., von Büdingen H.C. In multiple sclerosis oligoclonal bands connect to peripheral B cell responses. Ann. Neurol. 2013, 10.1002/ana.24088.
14. Howell O.W., Reeves C.A., Nicholas R., Carassiti D., Radotra B., Gentleman S.M., Serafini B., Aloisi F., Roncaroli F., Magliozzi R., Reynolds R. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
15. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
16. Hauser S.L., Waubant E., Arnold D.L. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
17. Freedman M.S., Kaplan J.M., Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J. Clin. Cell. Immunol. 2013, 4:1000152.
18. Sorensen P.S., Lisby S., Grove R., Derosier F., Shackelford S., Havrdova E., Drulovic J., Filippi M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014, 82:573-581.
19. Cortese I., Chaudhry V., So Y.T., Cantor F., Cornblath D.R., Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011, 76:294-300.
20. Harp C.T., Ireland S., Davis L.S., Remington G., Cassidy B., Cravens P.D., Stuve O., Lovett-Racke A.E., Eagar T.N., Greenberg B.M., Racke M.K., Cowell L.G., Karandikar N.J., Frohman E.M., Monson N.L. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 2010, 40:2942-2956.